US FDA Approves Venetoclax Plus Acalabrutinib as First All-Oral, Fixed-Duration Regimen for Untreated Chronic Lymphocytic Leukemia
The US FDA has approved a supplemental new drug application for the combination of Venclexta (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL), AbbVie announced on February 20, 2026. The VENCLEXTA acalabrutinib FDA approval establishes the regimen as the first and only all-oral, fixed-duration combination for treatment-naïve CLL, a disease that affects approximately 20,000 new patients annually in the United States and remains the most common form of adult leukemia in Western countries. The approval represents the first time two classes of oral targeted agents — a BCL-2 inhibitor and a BTK inhibitor — have been combined in an FDA-approved fixed-duration regimen for this patient population, and it extends the label of venetoclax, which AbbVie co-develops and co-commercializes with Roche's Genentech.
Dosing, Eligibility, and Regulatory Pathway
The approved regimen consists of venetoclax and acalabrutinib administered orally for a fixed duration of 14 cycles, each lasting 28 days. Venetoclax is introduced at cycle 3 with a five-week dose ramp-up schedule, a standard precaution designed to mitigate the risk of tumor lysis syndrome (TLS), a known complication of rapid cancer cell death associated with BCL-2 inhibition. The regimen is indicated for adult patients with previously untreated CLL. Notably, the AMPLIFY trial that supported the approval excluded patients with del(17p) or TP53 mutations, a high-risk genetic subgroup that typically requires separate treatment considerations. The approval was granted via a supplemental new drug application pathway. AbbVie did not specify whether the application received priority review, breakthrough therapy designation, or other expedited regulatory designations in its announcement.
AMPLIFY Trial Results and Clinical Evidence
The approval was supported by data from the Phase 3 AMPLIFY trial, a global, multicenter, open-label, randomized study sponsored by AstraZeneca that enrolled 984 patients with previously untreated CLL. The trial compared the fixed-duration venetoclax plus acalabrutinib combination (with or without obinutuzumab) against investigator's choice chemoimmunotherapy — either fludarabine-cyclophosphamide-rituximab (FCR) or bendamustine-rituximab (BR) — administered for six cycles. The primary endpoint was progression-free survival (PFS).
Results showed that the venetoclax acalabrutinib CLL combination reduced the risk of disease progression or death by 35% compared with chemoimmunotherapy (hazard ratio 0.65; 95% confidence interval 0.49–0.87; p=0.0038), the company said. Median PFS was not reached in the combination arm versus 47.6 months for the chemoimmunotherapy arm. An interim analysis presented at the American Society of Hematology annual meeting in 2024 reported that approximately 77% of patients receiving acalabrutinib plus venetoclax remained progression-free at three years. The safety profile of the combination was consistent with the known profiles of each agent used individually. The most common adverse reactions occurring in 20% or more of patients were neutropenia, headache, diarrhea, musculoskeletal pain, and COVID-19. The incidence of TLS in the combination arm was 0.3%. The most common serious adverse reactions at 2% or greater were COVID-19, including COVID-19 pneumonia (9%), second primary malignancies (2.7%), and neutropenia (2.1%). No new safety signals were observed, the company said.
Scientific Rationale and the Path to This Chronic Lymphocytic Leukemia Treatment
The biological logic underpinning this CLL combination treatment approved by the FDA rests on the simultaneous disruption of two distinct survival pathways that CLL cells exploit. Venetoclax is a first-in-class selective inhibitor of BCL-2, an anti-apoptotic protein that is overexpressed in CLL and prevents malignant B cells from undergoing programmed cell death. By binding BCL-2, venetoclax restores the apoptotic machinery, triggering cancer cell destruction. Acalabrutinib is a second-generation covalent inhibitor of Bruton's tyrosine kinase (BTK), a signaling enzyme downstream of the B-cell receptor that promotes CLL cell proliferation, survival, and tissue homing. The combination targets complementary mechanisms — one blocking a pro-survival protein, the other interrupting growth signaling — a rationale that has driven increasing interest in dual-targeted, fixed-duration CLL therapy across the field.